Download
Download by
Scanning QR Code
No matches yet
Please check network settings and try again Refresh
Loading
Futu Hot Stocks
    Latest News
    History record delete
      Quotes All >
      News All >
      Help All >

      • Download app

        Download app

      +
      Congratulations
      You've successfully got advanced quotes worth 5000 HKD
      Download APP >>
      Quotes
      Detailed Quotes
      Company Overview
      Company ProfileCompany Executives
      Financial Analysis
      Main CompositionKey IndicatorsFinancial Statement
      Multi-dimentional Analyses
      Company Valuation Capital Tracking Short Selling Data
      Futubull > Quotes > PHAR Pharming Group > Financial Statement > Income statement
      PHAR Pharming Group
      12.700
      +0.440+3.59%
      Post Mkt Price
      12.870
      +0.170+1.34%
      Income statement Balance sheet Cash flow
      YOY
      Do not show
      Hide blank lines
      (FY)2022/12/31(Q4)2022/12/31(Q3)2022/09/30(Q2)2022/06/30
      Total revenue
      3.39% 205.62M 3.51% 54.62M 2.60% 54.24M 0.95% 50.15M
      Operating revenue
      3.39% 205.62M 3.51% 54.62M 2.60% 54.24M 0.95% 50.15M
      Cost of revenue
      -16.93% 17.56M 11.20% 6.27M -60.39% 2.38M -13.24% 4.03M
      Gross profit
      5.81% 188.06M 2.59% 48.35M 10.68% 51.86M 2.42% 46.12M
      Operating expense
      7.00% 169.83M 34.68% 58.53M -9.41% 44.09M -17.17% 28.3M
      Selling and administrative expenses
      61.35% 131.82M 204.16% 46.55M 43.06% 32.4M 28.49% 27.95M
      -Selling and marketing expense
      44.34% 85.8M 86.21% 28.98M 34.07% 20.37M 39.00% 19.25M
      -General and administrative expense
      106.80% 46.02M 6,883.78% 17.57M 61.41% 12.03M 10.05% 8.69M
      Research and development costs
      -25.35% 52.53M -44.67% 10.89M -53.39% 12.34M 6.86% 14.43M
      Other operating expenses
      -350.44% -14.52M -85.82% 1.08M -42.51% -647K -1,186.03% -14.08M
      Operating profit
      -4.08% 18.23M -377.00% -10.18M 527.06% 7.76M 63.96% 17.82M
      Net non-operating interest income expense
      -111.23% -978K -292.69% -6.3M -5.91% 8.1M 52.42% -4.63M
      Non-operating interest income
      -- -- -- -- -5.75% 9.3M 60.23% -3.23M
      Non-operating interest expense
      -- -- -- -- -5.38% 1.25M -12.79% 1.35M
      Total other finance cost
      106.63% 978K -- -- -- -- -- --
      Other net income (expense)
      51.11% -2.27M 69.13% -1.61M -20.39% -6.58M 4.50% 6.37M
      Gain on sale of security
      -1,139.47% -1.19M -- -- -- -- -- --
      Earnings from equity interest
      -256.05% -1.08M -331.15% -423K -189.43% -110K -123.19% -109K
      Income before tax
      -35.06% 14.99M -1,143.39% -18.08M 602.42% 9.28M 170.42% 19.56M
      Income tax
      -81.46% 1.31M -946.06% -3.45M -89.77% 178K 171.92% 3.82M
      Net income
      -14.52% 13.67M -809.16% -14.63M 2,272.08% 9.1M 170.06% 15.74M
      Net income continuous Operations
      -14.52% 13.67M -809.16% -14.63M 2,272.08% 9.1M 170.06% 15.74M
      Minority interest income
      Net income attributable to the parent company
      -14.52% 13.67M -809.16% -14.63M 2,272.08% 9.1M 170.06% 15.74M
      Preferred stock dividends
      Other preferred stock dividends
      Net income attributable to common stockholders
      -14.52% 13.67M -809.16% -14.63M 2,272.08% 9.1M 170.06% 15.74M
      Basic earnings per share
      -16.00% 0.21 -833.33% -0.22 0.14 166.67% 0.24
      Diluted earnings per share
      -17.39% 0.19 -833.33% -0.22 1,400.00% 0.13 266.67% 0.22
      Dividend per share
      Currency Unit
      USDUSDUSDUSD
      Accounting Standards
      US-GAAPUS-GAAPUS-GAAPUS-GAAP

      FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

      Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

      The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%

      Company Overview More
      CEO： Dr. Sijmen (Simon) de Vries, M.D.
      Market： NASDAQ
      Futu Hot List
      USHKCN
      TradeSearchNews
      SymbolLatest price%Chg

      Loading...

      Watchlist
      Back to the Top